The global immunotherapy drugs market size was USD 202.5 Bn in 2022 and is likely to reach USD 425.5 Bn by 2031, expanding at a CAGR of 8.7% during 2023–2031. The market is propelled by the rising prevalence of chronic diseases such as cancer, autoimmune diseases, and kidney dysfunction along with the growing popularity of immunotherapy drugs.
Immunotherapy drugs are developed to stimulate the natural defense mechanism of the human immune system to treat various types of health complications such as autoimmune diseases, cancer, and infectious diseases. The human immune system comprises a network of cells, proteins, and organs that protects the human mechanism against infections by identifying and neutralizing disease-causing micro-organisms.
Immunotherapy drugs are made up of substances tested and approved by regulatory bodies that empower the immune system by harnessing the defense mechanism of the human body. Immunotherapy drugs improve the immune system of the human body by improving the cellular mechanism. The various types of immunotherapy drugs include chimeric antigen receptor (CAR) T-cell therapy, checkpoint inhibitors, cytokines, cancer vaccines, immunomodulators, oncolytic viruses, and monoclonal antibodies.
The market report finds that the COVID-19 pandemic positively affected the market due to the rising demand for immunotherapy drugs for the treatment of COVID-19. The preference for these drugs grew owing to their efficacy and safety.
The COVID-19 pandemic accelerated drug and vaccine development programs to curb the spread of the virus and contain the damage globally. The researchers emphasized finding the cure for COVID-19 by using immunotherapy drugs by enhancing the natural defense mechanism of the human body.
Immunotherapy Drugs Market Dynamics
Major Drivers
Rising prevalence of chronic diseases such as autoimmune diseases and cancer is expected to drive the market. According to data published by Pan American Health Organization on World Cancer Day (on 4th February 2023), the global cancer burden is likely to increase to 30 million new cancer cases by 2040. The cancer burden is likely to rise by approximately 60% over the next two decades.
The immunotherapy drugs such as checkpoint inhibitors, chimeric antigen receptor (CAR) T-cells, cytokines, and immunomodulators are used to treat a variety of cancers by activating the immune system to treat cancer. For instance, CAR T-cell therapy uses T-cells extracted from a patient’s blood. The T-cells are exposed to a variety of special viruses that enables T-cells to limit the growth of cancer-causing cells during cancer immunotherapy treatment.
Growing popularity of immunotherapy drugs due to the enhanced safety and efficacy of the treatments is anticipated to propel the market. Immunotherapy works on the principle of improving the natural defense mechanism of the human body thus it has minimum complications.
For example, some immunotherapy drugs such as CAR T-cells and inhibitors work on neutralizing the specific proteins present on the surface of the cancer cells in the human mechanism that prevents the T-cells from identifying and eliminating the cancerous cells. Such mechanisms enhance the natural defense of the human body thus it does not aggregate harmful chemical reactions.
Existing Restraints
The high cost of immunotherapy drugs is likely to impede the market. A 2020 estimate quoted in Statnews, an American health-oriented news website states that the average annual cost of healthcare and drugs was more than USD 42,000 while 30% of Americans with cancer face difficulty in paying the bills. More than 40% of patients had to shell out their life savings in the first two years of the cancer treatment.
Emerging Opportunities
Rising demand for biosimilars and monoclonal antibodies and a high approval rate for immunotherapy drugs are likely to create significant opportunities for the market. Biosimilars are complex biotherapeutic proteins that can be easily administered to the patient.
They are complex, large proteins used to detect and neutralize external attacks from viruses and bacteria. Biosimilars are expected to reduce treatment costs and improve treatment access associated with cancer treatment.
Scope of the Immunotherapy Drugs Market Report
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Immunotherapy Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Product Type (Monoclonal Antibodies, Checkpoint Inhibitors, Interferons, Vaccines, and Interleukins), Application (Cancer, Autoimmune Diseases, Infectious Diseases, and Others), and End-user (Hospitals, Specialty Clinics, and Research Institutes)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Novartis AG; AstraZeneca; F. Hoffmann-La Roche Ltd; Abbott; PerkinElmer Inc.; QIAGEN; Sanofi; Pfizer Inc.; AbbVie Inc.; GSK plc.; and Bayer AG
|
Immunotherapy Drugs Market Segment Insights
Based on product type, the immunotherapy drugs market is divided into monoclonal antibodies, checkpoint inhibitors, interferons, vaccines, and interleukins. The monoclonal antibodies segment is expected to expand at a major growth rate during the projection period owing to the enhanced efficacy and safety of monoclonal antibodies in the treatment of cancer and other chronic diseases. The rising popularity of targeted therapies that comprise antibodies to target specific antigens for curing diseases is likely to propel the market.
The checkpoint inhibitors segment is anticipated to hold a key share of the market in the coming years due to the efficacy of checkpoint inhibitors in the treatment of cancers such as lung and melanoma skin cancer. Checkpoint inhibitors are a type of targeted treatment that block certain types of proteins that prevent the immune system from attacking the cancer cells.
On the basis of application, the global market is segregated into cancer, autoimmune diseases, infectious diseases, and others. The cancer segment is projected to register a considerable CAGR during the forecast period due to the high efficacy rates and easy administration of immunotherapy drugs. Immunotherapy drugs either stop or slow down the progression of cancer cells in the human mechanism. For example, checkpoint inhibitors break the connection between the checkpoint and other proteins. When the connection breaks down, the T-cells in the body start attacking cancerous cells.
The autoimmune diseases segment is expected to hold a substantial share of the market in the forecast period due to the rising prevalence of autoimmune diseases and the growing adaptability of immunotherapy drugs to treat autoimmune diseases. Immunotherapy drugs help T-cells to identify and destroy the autoimmune disease-causing cells.
Based on end-user, the immunotherapy drugs market is segmented into hospitals, specialty clinics, and research institutes. The hospitals segment is expected to register a robust growth rate during the forecast period owing to the over-the-counter availability of immunotherapy drugs and follow-up consultation provided at the hospitals. Chronic patients need to visit the hospitals for regular checkups and diagnoses. Doctors prescribe them the immunotherapy drugs as per the requirement after a thorough diagnosis on the hospital premises.
The specialty clinics segment is expected to hold a substantial share of the market in the forecast period due to the easy accessibility and affordability provided by the specialty clinics. Specialty clinics are highly accessible as they are strategically located to provide healthcare services to patients at competitive and reasonable prices.
Regional Outlook
In terms of region, the global immunotherapy drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period owing to the rising prevalence of cancer and autoimmune diseases and the availability of novel immunotherapy drugs in the region. The government initiatives to promote immunotherapy drugs have created a conducive atmosphere for the growth of the market by providing reimbursement facilities to the patients who avail the immunotherapy treatments.
The market of Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to the rising prevalence of cancer and autoimmune diseases in the region and government initiatives to promote immunotherapy drugs as an effective line of treatment in emerging economies such as India and China. The research organizations are exploring various lines of treatments with safe and effective results. The rising cases of cancer and autoimmune diseases have prompted healthcare professionals to choose immunotherapy drugs as it has high efficacy rates and can be easily administered.
Segments
The immunotherapy drugs market has been segmented on the basis of
Product Type
- Monoclonal Antibodies
- Checkpoint Inhibitors
- Interferons
- Vaccines
- Interleukins
Application
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Others
End-user
- Hospitals
- Specialty Clinics
- Research Institutes
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Novartis AG
- AstraZeneca
- F. Hoffmann-La Roche Ltd
- Abbott
- PerkinElmer Inc.
- QIAGEN
- Sanofi
- Pfizer Inc.
- AbbVie Inc.
- GSK plc.
- Bayer AG
Competitive Landscape
Key players competing in the global immunotherapy drugs market are Novartis AG; AstraZeneca; F. Hoffmann-La Roche Ltd; Abbott; PerkinElmer Inc.; QIAGEN; Sanofi; Pfizer Inc.; AbbVie Inc.; GSK plc.; and Bayer AG
These companies in the immunotherapy drugs domain adopted development strategies including the launch of novel therapies, the development of research facilities with the help of mergers, acquisitions, partnerships, and collaboration, with the potential of partners to offer diversified products and services to consumers worldwide. For instance,
- On November 23, 2022, Bayer AG, one of the major manufacturers of immunotherapy drugs, announced that it has collaborated with three companies namely GRO Biosciences, Mozart Therapeutics, and Deka Biosciences to offer advanced techniques of targeted immunotherapies for autoimmune diseases. Mozart Therapeutics is using CD8 T cells to target T-cells while Deka Biosciences is using Cytokines proteins to treat cancer. It is anticipated that almost 8% of the world’s population is suffering from autoimmune diseases. The treatments developed by Bayer are likely to benefit the majority of people suffering from autoimmune diseases.
Request For Customization
Enquiry Before Buying
Speak With Analyst
